2001
Breast tumor contamination of PBSC harvests: tumor depletion by positive selection of CD34+ cells
Burgess J, Mills B, Griffith M, Mansour V, Weaver CH, Schwartzberg LS, Snyder EL, Krause DS, Yanovich S, Prilutskaya M, Umiel T, Moss TJ. Breast tumor contamination of PBSC harvests: tumor depletion by positive selection of CD34+ cells. Cytotherapy 2001, 3: 285-294. PMID: 12171717, DOI: 10.1080/146532401317070925.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntigens, CD34BiomarkersBreast NeoplasmsCell CountFemaleHematopoietic Stem Cell TransplantationHematopoietic Stem CellsHumansImmunohistochemistryImmunomagnetic SeparationLymphocytesMiddle AgedNeoplastic Cells, CirculatingPredictive Value of TestsReproducibility of ResultsConceptsCD34(-) cell fractionsBrCa cellsPBSC harvestsBRCA patientsCell fractionApheresis harvestsAutologous PBSC supportBreast cancer patientsMedian log depletionHighdose chemotherapyPBSC contaminationPBSC supportTumor contaminationCancer patientsICC detectionCell selectionLog depletionPatientsStandard immunocytochemistryImmunomagnetic enrichmentTumor cellsApheresis collectionsTumor depletionCell numberPrevalence
2000
Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial
Yanovich S, Mitsky P, Cornetta K, Maziarz R, Rosenfeld C, Krause D, Lotz J, Bitran J, Williams S, Preti R, Somlo G, Burtness B, Mills B. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial. Bone Marrow Transplantation 2000, 25: 1165-1174. PMID: 10849529, DOI: 10.1038/sj.bmt.1702415.Peer-Reviewed Original ResearchConceptsHigh-risk breast cancer patientsBreast cancer patientsMedian timeCancer patientsIsolated CD34Clinical trialsCell selection systemHematopoietic reconstitutionHigh-risk breast cancerCapacity of CD34Transplantation of CD34Absolute neutrophil countDuration of hospitalizationHigh-dose chemotherapyMulticenter clinical trialBone Marrow Transplantation (2000) 25Incidence of infectionPeripheral blood cellsInter-group differencesProgenitor cell graftsPlatelet engraftmentNeutrophil countCell transplantPlatelet transfusionsPlatelet count
1998
High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study
Chabannon C, Cornetta K, Lotz J, Rosenfeld C, Shlomchik M, Yanovitch S, Marolleau J, Sledge G, Novakovitch G, Srour E, Burtness B, Camerlo J, Gravis G, Lee-Fischer J, Faucher C, Chabbert I, Krause D, Maraninchi D, Mills B, Kunkel L, Oldham F, Blaise D, Viens P. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study. British Journal Of Cancer 1998, 78: 913-921. PMID: 9764583, PMCID: PMC2063121, DOI: 10.1038/bjc.1998.601.Peer-Reviewed Original ResearchConceptsPoor prognosis breast cancerHigh-dose chemotherapyHaematopoietic recoveryBreast cancerRecombinant human granulocyte colony-stimulating factorBlood cellsRandomized multicentre studyGranulocyte colony-stimulating factorHuman granulocyte colony-stimulating factorPeripheral blood cellsPeripheral blood CD34Peripheral blood progenitorsColony-stimulating factorMobilized blood cellsEpithelial tumor cellsEligible patientsStudy armsMulticentre studyPeripheral bloodConventional chemotherapyStudy groupPatientsChemotherapyBlood CD34CD34Cytosine Deaminase Adenoviral Vector and 5-Fluorocytosine Selectively Reduce Breast Cancer Cells 1 Million-Fold When They Contaminate Hematopoietic Cells: A Potential Purging Method for Autologous Transplantation
Garcia-Sanchez F, Pizzorno G, Fu SQ, Nanakorn T, Krause DS, Liang J, Adams E, Leffert JJ, Yin LH, Cooperberg MR, Hanania E, Wang WL, Won JH, Peng XY, Cote R, Brown R, Burtness B, Giles R, Crystal R, Deisseroth AB. Cytosine Deaminase Adenoviral Vector and 5-Fluorocytosine Selectively Reduce Breast Cancer Cells 1 Million-Fold When They Contaminate Hematopoietic Cells: A Potential Purging Method for Autologous Transplantation. Blood 1998, 92: 672-682. PMID: 9657770, DOI: 10.1182/blood.v92.2.672.Peer-Reviewed Original ResearchMeSH KeywordsAdenoviridaeAnimalsAntimetabolites, AntineoplasticBreast NeoplasmsCell DeathCytosine DeaminaseFemaleFlucytosineFluorouracilGene Transfer TechniquesGenetic VectorsHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHematopoietic Stem CellsHumansMaleMiceNucleoside DeaminasesProdrugsTransplantation, AutologousTumor Cells, CulturedConceptsBreast cancer cellsPeripheral blood mononuclear cellsBreast cancer patientsCancer patientsCytosine deaminase geneHuman mammary epithelial cellsAdenoviral vectorCancer cellsHours of exposureHematopoietic cellsAutologous stem cell productsMarrow cellsEscherichia coli cytosine deaminase geneReplication-incompetent adenoviral vectorEpithelial cellsChemotherapy-induced myelosuppressionBreast cancer cell line MCF-7Blood mononuclear cellsEarly hematopoietic precursor cellsMale donor miceCancer cell line MCF-7Fluorescence-activated cell sorting (FACS) analysisMCF-7 breast cancer cellsNormal human mammary epithelial cellsMDA-MB-453